Welcome to our dedicated page for Iterum Therapeutics Plc news (Ticker: ITRM), a resource for investors and traders seeking the latest updates and insights on Iterum Therapeutics Plc stock.
Iterum Therapeutics Plc (ITRM) is a clinical-stage pharmaceutical company pioneering treatments for multi-drug resistant infections. This page provides investors and industry professionals with verified news and press releases about ITRM's advancements in oral and IV anti-infectives.
Access real-time updates on clinical trials, regulatory milestones like Qualified Infectious Disease Product (QIDP) designations, and strategic partnerships. Our curated repository ensures you stay informed about developments in antibiotic resistance solutions without promotional bias.
Key coverage areas include Phase 3 trial results, FDA communications, financial reporting, and R&D collaborations. All content is sourced directly from Iterum Therapeutics and reputable financial publications to ensure accuracy.
Bookmark this page for streamlined access to ITRM's latest progress in addressing global health challenges through differentiated anti-infective therapies.
Iterum Therapeutics plc (Nasdaq: ITRM) will report its first quarter 2024 financial results on May 13, 2024. The company focuses on developing oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens. A conference call will be held to discuss financial results and business updates.
Iterum Therapeutics has resubmitted its New Drug Application for oral sulopenem to the U.S. FDA for the treatment of uncomplicated urinary tract infections. The potential approval of oral sulopenem, the first oral penem in the U.S. and the second new oral treatment for uUTIs in over 25 years, could benefit an estimated 40 million women suffering from uUTIs annually in the U.S. The NDA resubmission includes data from phase 3 clinical trials showing oral sulopenem's efficacy and safety, positioning it as a promising new antibiotic option.
FAQ
What is the current stock price of Iterum Therapeutics Plc (ITRM)?
What is the market cap of Iterum Therapeutics Plc (ITRM)?
